TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Primary Immunodeficiency Drugs Market, Global Outlook and Forecast 2023-2029

Primary Immunodeficiency Drugs Market, Global Outlook and Forecast 2023-2029

  • Category:Life Sciences
  • Published on : 12 April 2023
  • Pages :73
  • Formats:
  • Report Code:SMR-7638304
OfferClick for best price

Best Price: $2600

Primary Immunodeficiency Drugs Market Size, Share 2023


Drugs for the treatment of primary immunodeficiency diseases

This report aims to provide a comprehensive presentation of the global market for Primary Immunodeficiency Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Immunodeficiency Drugs. This report contains market size and forecasts of Primary Immunodeficiency Drugs in global, including the following market information:

Global Primary Immunodeficiency Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)

Global Primary Immunodeficiency Drugs Market Sales, 2018-2023, 2024-2029, (K Units)

Global top five Primary Immunodeficiency Drugs companies in 2022 (%)

The global Primary Immunodeficiency Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.

Cytokines Segment to Reach $ Million by 2029, with a % CAGR in next six years.

The global key manufacturers of Primary Immunodeficiency Drugs include ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc. and Pharming Group, etc. in 2022, the global top five players have a share approximately % in terms of revenue.

We surveyed the Primary Immunodeficiency Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Primary Immunodeficiency Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)

Global Primary Immunodeficiency Drugs Market Segment Percentages, by Type, 2022 (%)

Cytokines

Anti Cytokine Antibodies

Signal Molecule Inhibitor

Global Primary Immunodeficiency Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)

Global Primary Immunodeficiency Drugs Market Segment Percentages, by Application, 2022 (%)

Hospital

Specialist Clinic

Othere

Global Primary Immunodeficiency Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)

Global Primary Immunodeficiency Drugs Market Segment Percentages, By Region and Country, 2022 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Primary Immunodeficiency Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)

Key companies Primary Immunodeficiency Drugs revenues share in global market, 2022 (%)

Key companies Primary Immunodeficiency Drugs sales in global market, 2018-2023 (Estimated), (K Units)

Key companies Primary Immunodeficiency Drugs sales share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

ADMA Biologics, Inc.

CSL Behring, LLC

Octapharma

Takeda Pharmaceutical Company

Grifols Biologicals, Inc.

Baxter

Kedrion Biopharma

BPL Inc.

Pharming Group

Shire

Chengdu Rongsheng Pharmaceutical Co., Ltd

Outline of Major Chapters:

Chapter 1: Introduces the definition of Primary Immunodeficiency Drugs, market overview.

Chapter 2: Global Primary Immunodeficiency Drugs market size in revenue and volume.

Chapter 3: Detailed analysis of Primary Immunodeficiency Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Primary Immunodeficiency Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Global Primary Immunodeficiency Drugs capacity by region & country.

Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 11: The main points and conclusions of the report.

Report Attributes Report Details
Report Title Primary Immunodeficiency Drugs Market, Global Outlook and Forecast 2023-2029
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2022
Forecast Year 2030
Number of Pages 73 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Introduction to Research & Analysis Reports
1.1 Primary Immunodeficiency Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Primary Immunodeficiency Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Primary Immunodeficiency Drugs Overall Market Size
2.1 Global Primary Immunodeficiency Drugs Market Size: 2022 VS 2029
2.2 Global Primary Immunodeficiency Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Primary Immunodeficiency Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Primary Immunodeficiency Drugs Players in Global Market
3.2 Top Global Primary Immunodeficiency Drugs Companies Ranked by Revenue
3.3 Global Primary Immunodeficiency Drugs Revenue by Companies
3.4 Global Primary Immunodeficiency Drugs Sales by Companies
3.5 Global Primary Immunodeficiency Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Primary Immunodeficiency Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Primary Immunodeficiency Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Primary Immunodeficiency Drugs Players in Global Market
3.8.1 List of Global Tier 1 Primary Immunodeficiency Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Primary Immunodeficiency Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Primary Immunodeficiency Drugs Market Size Markets, 2022 & 2029
4.1.2 Cytokines
4.1.3 Anti Cytokine Antibodies
4.1.4 Signal Molecule Inhibitor
4.2 By Type - Global Primary Immunodeficiency Drugs Revenue & Forecasts
4.2.1 By Type - Global Primary Immunodeficiency Drugs Revenue, 2018-2023
4.2.2 By Type - Global Primary Immunodeficiency Drugs Revenue, 2024-2029
4.2.3 By Type - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
4.3 By Type - Global Primary Immunodeficiency Drugs Sales & Forecasts
4.3.1 By Type - Global Primary Immunodeficiency Drugs Sales, 2018-2023
4.3.2 By Type - Global Primary Immunodeficiency Drugs Sales, 2024-2029
4.3.3 By Type - Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
4.4 By Type - Global Primary Immunodeficiency Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Primary Immunodeficiency Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Specialist Clinic
5.1.4 Othere
5.2 By Application - Global Primary Immunodeficiency Drugs Revenue & Forecasts
5.2.1 By Application - Global Primary Immunodeficiency Drugs Revenue, 2018-2023
5.2.2 By Application - Global Primary Immunodeficiency Drugs Revenue, 2024-2029
5.2.3 By Application - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
5.3 By Application - Global Primary Immunodeficiency Drugs Sales & Forecasts
5.3.1 By Application - Global Primary Immunodeficiency Drugs Sales, 2018-2023
5.3.2 By Application - Global Primary Immunodeficiency Drugs Sales, 2024-2029
5.3.3 By Application - Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
5.4 By Application - Global Primary Immunodeficiency Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Primary Immunodeficiency Drugs Market Size, 2022 & 2029
6.2 By Region - Global Primary Immunodeficiency Drugs Revenue & Forecasts
6.2.1 By Region - Global Primary Immunodeficiency Drugs Revenue, 2018-2023
6.2.2 By Region - Global Primary Immunodeficiency Drugs Revenue, 2024-2029
6.2.3 By Region - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
6.3 By Region - Global Primary Immunodeficiency Drugs Sales & Forecasts
6.3.1 By Region - Global Primary Immunodeficiency Drugs Sales, 2018-2023
6.3.2 By Region - Global Primary Immunodeficiency Drugs Sales, 2024-2029
6.3.3 By Region - Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Primary Immunodeficiency Drugs Revenue, 2018-2029
6.4.2 By Country - North America Primary Immunodeficiency Drugs Sales, 2018-2029
6.4.3 US Primary Immunodeficiency Drugs Market Size, 2018-2029
6.4.4 Canada Primary Immunodeficiency Drugs Market Size, 2018-2029
6.4.5 Mexico Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Primary Immunodeficiency Drugs Revenue, 2018-2029
6.5.2 By Country - Europe Primary Immunodeficiency Drugs Sales, 2018-2029
6.5.3 Germany Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.4 France Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.5 U.K. Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.6 Italy Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.7 Russia Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.9 Benelux Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Primary Immunodeficiency Drugs Revenue, 2018-2029
6.6.2 By Region - Asia Primary Immunodeficiency Drugs Sales, 2018-2029
6.6.3 China Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.4 Japan Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.5 South Korea Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.7 India Primary Immunodeficiency Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Primary Immunodeficiency Drugs Revenue, 2018-2029
6.7.2 By Country - South America Primary Immunodeficiency Drugs Sales, 2018-2029
6.7.3 Brazil Primary Immunodeficiency Drugs Market Size, 2018-2029
6.7.4 Argentina Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Primary Immunodeficiency Drugs Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Primary Immunodeficiency Drugs Sales, 2018-2029
6.8.3 Turkey Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8.4 Israel Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8.6 UAE Primary Immunodeficiency Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 ADMA Biologics, Inc.
7.1.1 ADMA Biologics, Inc. Company Summary
7.1.2 ADMA Biologics, Inc. Business Overview
7.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Major Product Offerings
7.1.4 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.1.5 ADMA Biologics, Inc. Key News & Latest Developments
7.2 CSL Behring, LLC
7.2.1 CSL Behring, LLC Company Summary
7.2.2 CSL Behring, LLC Business Overview
7.2.3 CSL Behring, LLC Primary Immunodeficiency Drugs Major Product Offerings
7.2.4 CSL Behring, LLC Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.2.5 CSL Behring, LLC Key News & Latest Developments
7.3 Octapharma
7.3.1 Octapharma Company Summary
7.3.2 Octapharma Business Overview
7.3.3 Octapharma Primary Immunodeficiency Drugs Major Product Offerings
7.3.4 Octapharma Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Octapharma Key News & Latest Developments
7.4 Takeda Pharmaceutical Company
7.4.1 Takeda Pharmaceutical Company Company Summary
7.4.2 Takeda Pharmaceutical Company Business Overview
7.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Major Product Offerings
7.4.4 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Takeda Pharmaceutical Company Key News & Latest Developments
7.5 Grifols Biologicals, Inc.
7.5.1 Grifols Biologicals, Inc. Company Summary
7.5.2 Grifols Biologicals, Inc. Business Overview
7.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Major Product Offerings
7.5.4 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Grifols Biologicals, Inc. Key News & Latest Developments
7.6 Baxter
7.6.1 Baxter Company Summary
7.6.2 Baxter Business Overview
7.6.3 Baxter Primary Immunodeficiency Drugs Major Product Offerings
7.6.4 Baxter Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Baxter Key News & Latest Developments
7.7 Kedrion Biopharma
7.7.1 Kedrion Biopharma Company Summary
7.7.2 Kedrion Biopharma Business Overview
7.7.3 Kedrion Biopharma Primary Immunodeficiency Drugs Major Product Offerings
7.7.4 Kedrion Biopharma Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Kedrion Biopharma Key News & Latest Developments
7.8 BPL Inc.
7.8.1 BPL Inc. Company Summary
7.8.2 BPL Inc. Business Overview
7.8.3 BPL Inc. Primary Immunodeficiency Drugs Major Product Offerings
7.8.4 BPL Inc. Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.8.5 BPL Inc. Key News & Latest Developments
7.9 Pharming Group
7.9.1 Pharming Group Company Summary
7.9.2 Pharming Group Business Overview
7.9.3 Pharming Group Primary Immunodeficiency Drugs Major Product Offerings
7.9.4 Pharming Group Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Pharming Group Key News & Latest Developments
7.10 Shire
7.10.1 Shire Company Summary
7.10.2 Shire Business Overview
7.10.3 Shire Primary Immunodeficiency Drugs Major Product Offerings
7.10.4 Shire Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Shire Key News & Latest Developments
7.11 Chengdu Rongsheng Pharmaceutical Co., Ltd
7.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Company Summary
7.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Business Overview
7.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Major Product Offerings
7.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Key News & Latest Developments
8 Global Primary Immunodeficiency Drugs Production Capacity, Analysis
8.1 Global Primary Immunodeficiency Drugs Production Capacity, 2018-2029
8.2 Primary Immunodeficiency Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Primary Immunodeficiency Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Primary Immunodeficiency Drugs Supply Chain Analysis
10.1 Primary Immunodeficiency Drugs Industry Value Chain
10.2 Primary Immunodeficiency Drugs Upstream Market
10.3 Primary Immunodeficiency Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Primary Immunodeficiency Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Key Players of Primary Immunodeficiency Drugs in Global Market
Table 2. Top Primary Immunodeficiency Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Primary Immunodeficiency Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Primary Immunodeficiency Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Primary Immunodeficiency Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Primary Immunodeficiency Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Primary Immunodeficiency Drugs Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Primary Immunodeficiency Drugs Product Type
Table 9. List of Global Tier 1 Primary Immunodeficiency Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Primary Immunodeficiency Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Primary Immunodeficiency Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Primary Immunodeficiency Drugs Sales (K Units), 2024-2029
Table 16. By Application ? Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Primary Immunodeficiency Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Primary Immunodeficiency Drugs Sales (K Units), 2024-2029
Table 21. By Region ? Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Primary Immunodeficiency Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Primary Immunodeficiency Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Primary Immunodeficiency Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Primary Immunodeficiency Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Primary Immunodeficiency Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Primary Immunodeficiency Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Primary Immunodeficiency Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Primary Immunodeficiency Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Primary Immunodeficiency Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Primary Immunodeficiency Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Primary Immunodeficiency Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Primary Immunodeficiency Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Primary Immunodeficiency Drugs Sales, (K Units), 2024-2029
Table 46. ADMA Biologics, Inc. Company Summary
Table 47. ADMA Biologics, Inc. Primary Immunodeficiency Drugs Product Offerings
Table 48. ADMA Biologics, Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. ADMA Biologics, Inc. Key News & Latest Developments
Table 50. CSL Behring, LLC Company Summary
Table 51. CSL Behring, LLC Primary Immunodeficiency Drugs Product Offerings
Table 52. CSL Behring, LLC Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. CSL Behring, LLC Key News & Latest Developments
Table 54. Octapharma Company Summary
Table 55. Octapharma Primary Immunodeficiency Drugs Product Offerings
Table 56. Octapharma Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Octapharma Key News & Latest Developments
Table 58. Takeda Pharmaceutical Company Company Summary
Table 59. Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Product Offerings
Table 60. Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Takeda Pharmaceutical Company Key News & Latest Developments
Table 62. Grifols Biologicals, Inc. Company Summary
Table 63. Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Product Offerings
Table 64. Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Grifols Biologicals, Inc. Key News & Latest Developments
Table 66. Baxter Company Summary
Table 67. Baxter Primary Immunodeficiency Drugs Product Offerings
Table 68. Baxter Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Baxter Key News & Latest Developments
Table 70. Kedrion Biopharma Company Summary
Table 71. Kedrion Biopharma Primary Immunodeficiency Drugs Product Offerings
Table 72. Kedrion Biopharma Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Kedrion Biopharma Key News & Latest Developments
Table 74. BPL Inc. Company Summary
Table 75. BPL Inc. Primary Immunodeficiency Drugs Product Offerings
Table 76. BPL Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. BPL Inc. Key News & Latest Developments
Table 78. Pharming Group Company Summary
Table 79. Pharming Group Primary Immunodeficiency Drugs Product Offerings
Table 80. Pharming Group Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Pharming Group Key News & Latest Developments
Table 82. Shire Company Summary
Table 83. Shire Primary Immunodeficiency Drugs Product Offerings
Table 84. Shire Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Shire Key News & Latest Developments
Table 86. Chengdu Rongsheng Pharmaceutical Co., Ltd Company Summary
Table 87. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Product Offerings
Table 88. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Chengdu Rongsheng Pharmaceutical Co., Ltd Key News & Latest Developments
Table 90. Primary Immunodeficiency Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 91. Global Primary Immunodeficiency Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 92. Global Primary Immunodeficiency Drugs Production by Region, 2018-2023 (K Units)
Table 93. Global Primary Immunodeficiency Drugs Production by Region, 2024-2029 (K Units)
Table 94. Primary Immunodeficiency Drugs Market Opportunities & Trends in Global Market
Table 95. Primary Immunodeficiency Drugs Market Drivers in Global Market
Table 96. Primary Immunodeficiency Drugs Market Restraints in Global Market
Table 97. Primary Immunodeficiency Drugs Raw Materials
Table 98. Primary Immunodeficiency Drugs Raw Materials Suppliers in Global Market
Table 99. Typical Primary Immunodeficiency Drugs Downstream
Table 100. Primary Immunodeficiency Drugs Downstream Clients in Global Market
Table 101. Primary Immunodeficiency Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Primary Immunodeficiency Drugs Segment by Type in 2022
Figure 2. Primary Immunodeficiency Drugs Segment by Application in 2022
Figure 3. Global Primary Immunodeficiency Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Primary Immunodeficiency Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Primary Immunodeficiency Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Primary Immunodeficiency Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Primary Immunodeficiency Drugs Revenue in 2022
Figure 9. By Type - Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Primary Immunodeficiency Drugs Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Primary Immunodeficiency Drugs Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 23. US Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 28. Germany Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 37. China Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Primary Immunodeficiency Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Primary Immunodeficiency Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Primary Immunodeficiency Drugs by Region, 2022 VS 2029
Figure 54. Primary Immunodeficiency Drugs Industry Value Chain
Figure 55. Marketing Channels

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount